What is needed to ensure that cell- and gene-based therapies for sickle cell disease and HIV are accessible, available and affordable in low middle income countries - following the lead of HIV treatment? Cell and gene therapies (CGT) are transforming healthcare but are prohibitively expensive ($2m) and geographically limited in availability (primarily United States). Recently two CGT technologies (cures) were approved for sickle cell disease (SCD) which has a global majority prevalence that matches HIV. Currently, more than 40 clinical trials of CGT for treatment of HIV are in progress offering hope that a cure for HIV may also be possible using CGT. This session will review the history of the HIV advocacy response and connect SCD and HIV advocate experience to discuss how we ensure CGTs for HIV and SCD are available, accessible and affordable for all people regardless of their location.